Dr Mark Zimmerman
Mark Zimmerman received his bachelors in Biology from Syracuse University and his masters and doctorate in Biomedical Engineering from Rutgers University. Mark joined UMD-New Jersey Medical School as an Assistant Professor in 1986 and left in 1996 as an Associate Professor of Surgery with tenure. His research interests spanned musculoskeletal tissue engineering, sports medicine, trauma, and spine biomechanics and biomaterials.
Mark joined Johnson and Johnson in 1997 as a principal scientist/group leader and transitioned into regenerative medicine projects related to orthopaedic surgery, wound healing, vascular biology, and diabetes. Mark was appointed executive director of a Lifescan incubator, BetaLogics, in July 2002. BetaLogics transitioned to a Johnson and Johnson Internal Venture in 2004. The mission of BetaLogics is to discover and develop a cellular product to treat diabetes. Mark was appointed Venture Leader/Vice President of BetaLogics in 2009.
Mark is a fellow in the American Institute of Mechanical and Biomedical Engineers, a member of numerous societies (Tissue Engineering Society, International Society for Stem Cell Research, the International Society for Cell Therapy, the American Diabetes Association, the American Society of Mechanical Engineers, the Biomaterials Society). Mark has authored 44 peer-reviewed publications, 10 book chapters, 136 abstracts and is an inventor on 24 patents.